{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:13Z","timestamp":1787988013980,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite decades of technical development, dynamic PET and parametric imaging have not yet achieved widespread clinical implementation in oncology, largely due to technical complexity and the limited number of clinical scenarios in which clear additional value over static imaging has been demonstrated. We hypothesized that liver metastases from\u00a0uveal melanoma\u2014a tumor entity often characterized by low tumor-to-background contrast on static imaging\u2014 may represent a particularly promising application for dynamic PET imaging. Accordingly, we aimed to determine whether dynamic Patlak parametric imaging improves lesion detectability and conspicuity compared with standard (50\u201360 min) and delayed (70\u201385 min) static standardized uptake value (SUV) imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      Twenty-six patients with uveal melanoma and a total of 126 tumor lesions, including 58 liver metastases and 68 other metastases, were prospectively enrolled. All patients underwent a 60\u00a0min dynamic data acquisition (skull to upper thigh) followed by whole-body [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT imaging at 70\u00a0min post-injection. Three image datasets were generated and compared: (1) Direct Patlak K\n                      <jats:sub>i<\/jats:sub>\n                      parametric images derived from dynamic acquisition at 30\u201360\u00a0min post-injection, (2) standard static SUV images reconstructed from same dynamic acquisition at 50\u201360\u00a0min post-injection (standardSUV), and (3) delayed static SUV images acquired at 70\u201385\u00a0min post-injection (lateSUV). All three image sets were assessed qualitatively for lesion detectability and quantitative analysis was performed for all 126 lesions using tumor-to-background ratio (TBR\n                      <jats:sub>mean<\/jats:sub>\n                      ) measurements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No significant differences were observed among the three imaging approaches with respect to the total number of detected tumor lesions. However, one discordant finding was noted: a true-positive liver metastasis was identified on Patlak K\n                      <jats:sub>i<\/jats:sub>\n                      imaging and subsequently confirmed by MRI, but was not clearly visualized on static SUV images. Qualitatively, for liver and other metastases, Patlak K\n                      <jats:sub>i<\/jats:sub>\n                      and lateSUV images showed significantly higher TBR\n                      <jats:sub>mean<\/jats:sub>\n                      values than standardSUV, with mean increases of\u2009~\u20092.1\u20132.3-fold for K\n                      <jats:sub>i<\/jats:sub>\n                      and\u2009~\u20091.3-fold for lateSUV. Furthermore, Patlak K\n                      <jats:sub>i<\/jats:sub>\n                      yielded significantly higher TBR\n                      <jats:sub>mean<\/jats:sub>\n                      than lateSUV (52\/58 and 65\/68) and standardSUV (57\/58 and 67\/68) for liver and other metastases, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although lesion detection rates were not significantly increased, dynamic acquisition with Patlak parametric imaging provided a robust and less timing-dependent method to enhance tumor-to-background contrast compared with\u00a0static SUV imaging and may yield discordant findings with additional clinical value in selected cases. Overall, Patlak imaging may therefore represent a complementary contrast-optimization approach for evaluating liver metastases from uveal melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08014-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:10:42Z","timestamp":1781939442000},"page":"6549-6558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are liver metastases from\u00a0uveal melanoma\u00a0a clinical indication for dynamic PET? A comparison of Patlak parametric imaging with standard and delayed static SUV imaging using long axial field-of-view PET\/CT"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-7888","authenticated-orcid":false,"given":"Leyun","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"Suppl 1","key":"8014_CR1","first-page":"144S","volume":"57","author":"H Jadvar","year":"2016","unstructured":"Jadvar H. FDG PET in oncology: basics and clinical applications. J Nucl Med. 2016;57(Suppl 1):144S-149S.","journal-title":"J Nucl Med"},{"issue":"2","key":"8014_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00259-018-4153-6","volume":"46","author":"A Rahmim","year":"2019","unstructured":"Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, et al. Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging. 2019;46(2):501\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"8014_CR3","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S-20S.","journal-title":"J Nucl Med"},{"issue":"3","key":"8014_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1053\/j.semnuclmed.2021.10.002","volume":"52","author":"A Dimitrakopoulou-Strauss","year":"2022","unstructured":"Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Parametric imaging with dynamic PET for oncological applications: protocols, interpretation, current applications and limitations for clinical use. Semin Nucl Med. 2022;52(3):312\u201329.","journal-title":"Semin Nucl Med"},{"key":"8014_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00259-020-04843-6","volume":"48","author":"A Dimitrakopoulou-Strauss","year":"2021","unstructured":"Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48:21\u201339.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8014_CR6","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8014_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials. Arch Ophthalmol. 2005;123:1639\u201343.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"8014_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38\u201344.","journal-title":"Br J Ophthalmol"},{"key":"8014_CR9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.ejca.2015.07.013","volume":"51","author":"P Nathan","year":"2015","unstructured":"Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51:2404\u201312.","journal-title":"Eur J Cancer"},{"key":"8014_CR10","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1007\/s00259-009-1175-0","volume":"36","author":"K Strobel","year":"2009","unstructured":"Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer DR, Imhof L, et al. Limited value of 18F-FDG PET\/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1774\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"8014_CR11","first-page":"1412","volume":"42","author":"H Zhuang","year":"2001","unstructured":"Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412\u20137.","journal-title":"J Nucl Med"},{"issue":"10","key":"8014_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s002590050593","volume":"26","author":"R Hustinx","year":"1999","unstructured":"Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26(10):1345\u201358.","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"8014_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jcbfm.1983.1","volume":"3","author":"CS Patlak","year":"1983","unstructured":"Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"8014_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ctrv.2012.01.002","volume":"38","author":"F Spagnolo","year":"2012","unstructured":"Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012;38(5):549\u201353.","journal-title":"Cancer Treat Rev"},{"key":"8014_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881\u20135.","journal-title":"Ophthalmology"},{"issue":"4","key":"8014_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.aopr.2024.10.001","volume":"4","author":"X Hou","year":"2024","unstructured":"Hou X, Rokohl AC, Li X, Guo Y, Ju X, Fan W, et al. Global incidence and prevalence in uveal melanoma. Adv Ophthalmol Pract Res. 2024;4(4):226\u201332.","journal-title":"Adv Ophthalmol Pract Res"},{"issue":"5","key":"8014_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/14796694.4.5.629","volume":"4","author":"S Landreville","year":"2008","unstructured":"Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol. 2008;4(5):629\u201336.","journal-title":"Future Oncol"},{"key":"8014_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ohc.2004.07.003","volume":"18","author":"AD Singh","year":"2005","unstructured":"Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am. 2005;18:143\u201350.","journal-title":"Ophthalmol Clin North Am"},{"key":"8014_CR19","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-025-07504-8","volume":"53","author":"C Sachpekidis","year":"2026","unstructured":"Sachpekidis C, Machiraju D, Strauss DS, Pan L, Afshar-Oromieh A, Dimitrakopoulou-Strauss A, et al. Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET\/CT study. Eur J Nucl Med Mol Imaging. 2026;53:1570\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8014_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.iio.0000195852.08453.de","volume":"46","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151\u201366.","journal-title":"Int Ophthalmol Clin"},{"key":"8014_CR21","unstructured":"Food and Drug Administration. FDA DISCO Burst Edition: FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. Published January 26, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma"},{"key":"8014_CR22","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389:2256\u201366.","journal-title":"N Engl J Med"},{"key":"8014_CR23","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1088\/0031-9155\/58\/20\/7391","volume":"58","author":"NA Karakatsanis","year":"2013","unstructured":"Karakatsanis NA, Lodge MA, Tahari AK, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. Phys Med Biol. 2013;58:7391\u2013418.","journal-title":"Phys Med Biol"},{"key":"8014_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.neuroimage.2008.07.035","volume":"43","author":"JE Mourik","year":"2008","unstructured":"Mourik JE, van Velden FH, Lubberink M, Kloet RW, van Berckel BN, Lammertsma AA, et al. Image derived input functions for dynamic High Resolution Research Tomograph PET brain studies. Neuroimage. 2008;43:676\u201386.","journal-title":"Neuroimage"},{"key":"8014_CR25","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s00259-021-05623-6","volume":"49","author":"H Sari","year":"2022","unstructured":"Sari H, Mingels C, Alberts I, Hu J, Buesser D, Shah V, et al. First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients. Eur J Nucl Med Mol Imaging. 2022;49:1997\u20132009.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8014_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00259-020-05007-2","volume":"48","author":"AH Dias","year":"2021","unstructured":"Dias AH, Pedersen MF, Danielsen H, Munk OL, Gormsen LC. Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body 18F-FDG PET\/CT scans. Eur J Nucl Med Mol Imaging. 2021;48:837\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8014_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40658-022-00490-y","volume":"9","author":"AH Dias","year":"2022","unstructured":"Dias AH, Smith AM, Shah V, Pigg D, Gormsen LC, Munk OL. Clinical validation of a population-based input function for 20-min dynamic whole-body 18F-FDG multiparametric PET imaging. EJNMMI Phys. 2022;9:60.","journal-title":"EJNMMI Phys"},{"key":"8014_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-024-06879-4","volume":"52","author":"L Pan","year":"2025","unstructured":"Pan L, Sachpekidis C, Hassel JC, Christopoulos P, Dimitrakopoulou-Strauss A. Impact of different parametric Patlak imaging approaches and comparison with a 2-tissue compartment pharmacokinetic model with a long axial field-of-view (LAFOV) PET\/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2025;52:623\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8014_CR29","doi-asserted-by":"crossref","unstructured":"Sivapathasundaram A, Buffon A, Ghidaglia J, Jentreau Y, Gomez L, et al. Regional impact of time-to-equilibrium on indirect Patlak whole-body parametric imaging: a multi-tissue class analysis at the entire body level. EJNMMI Phys. 2025;12:96.","DOI":"10.1186\/s40658-025-00809-5"},{"issue":"1","key":"8014_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2967\/jnumed.116.184028","volume":"59","author":"SR Cherry","year":"2018","unstructured":"Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59(1):3\u201312.","journal-title":"J Nucl Med"},{"key":"8014_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2967\/jnumed.119.226498","volume":"60","author":"RD Badawi","year":"2019","unstructured":"Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60:299\u2013303.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08014-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:58Z","timestamp":1787986858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08014-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8014"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08014-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants enrolled in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to publish has been received from all participants.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica C. Hassel discloses Speaker: Amgen, Bristol-Myers Squibb, GSK, Immunocore, Merck Sharp and Dohme, Novartis Pharma, Pierre Fabre, Sanofi-Aventis U.S. LLC; Sunpharma; Research grant\/contract: Bristol-Myers Squibb, Sanofi, Sunpharma; Consultant\/Advisory Board: Bristol-Myers Squibb, GSK, Immunocore, Merck Sharp and Dohme, Novartis Pharma, Pierre Fabre Pharmaceuticals Inc., Philogen, Onkowissen, Sanofi-Aventis U.S. LLC, Sun Pharmaceutical Industries Inc. Christos Sachpekidis is an associate editor in this journal. Antonia Dimitrakopoulou-Strauss is\u00a0a\u00a0member of the editorial board of this journal.\u00a0All other authors declare no conflicts of interest.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}